Lumacaftor acts as a CFTR corrector, targeting the F508del mutation, which is the most common mutation in cystic fibrosis. This mutation leads to the production of a misfolded CFTR protein that is degraded before it reaches the cell surface. Lumacaftor helps the CFTR protein fold correctly and reach the cell surface where it can function properly.
